SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila gets final approval from USFDA for Clobazam Tablets

23 Oct 2018 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Clobazam Tablets, (US RLD-ONFI Tablet), 10 mg and 20 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Clobazam is used in combination with other medications to treat seizures caused by a paediatric epilepsy syndrome (termed as Lennox-Gastaut syndrome) that also causes developmental and behavioural problems.

The group now has 224 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

953.55 14.65 (1.56%)
11-May-2026 14:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1873.00
Dr. Reddys Lab 1289.40
Cipla 1307.55
Zydus Lifesciences 953.55
Lupin 2273.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×